CN Patent

CN1240718C — 人胰岛素衍生物的聚集体

Assigned to Novo Nordisk AS · Expires 2006-02-08 · 20y expired

What this patent protects

本发明公开了具有持久作用曲线的人胰岛素衍生物的水溶性聚集体。可溶性胰岛素衍生物作用的延长与一种新机理有关。该机理是基于部分或完全形成可溶性聚集体形式的衍生物，该聚集体形式的特征是在所定义的凝胶过滤系统中，其尺寸大于醛缩酶(Mw＝158KDa)。

USPTO Abstract

本发明公开了具有持久作用曲线的人胰岛素衍生物的水溶性聚集体。可溶性胰岛素衍生物作用的延长与一种新机理有关。该机理是基于部分或完全形成可溶性聚集体形式的衍生物，该聚集体形式的特征是在所定义的凝胶过滤系统中，其尺寸大于醛缩酶(Mw＝158KDa)。

Drugs covered by this patent

Patent Metadata

Patent number
CN1240718C
Jurisdiction
CN
Classification
—
Expires
2006-02-08
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.